SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001562762-22-000230
Filing Date
2022-05-09
Accepted
2022-05-09 06:39:29
Documents
80
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 vaxx-20220331.htm   iXBRL 10-Q 1193170
2 exhibit42.htm EX-4.2 77825
3 exhibit311.htm EX-31.1 10984
4 exhibit312.htm EX-31.2 11074
5 exhibit321.htm EX-32.1 6212
  Complete submission text file 0001562762-22-000230.txt   6521677

Data Files

Seq Description Document Type Size
6 vaxx-20220331.xsd EX-101.SCH 67549
7 vaxx-20220331_cal.xml EX-101.CAL 79448
8 vaxx-20220331_def.xml EX-101.DEF 453405
9 vaxx-20220331_lab.xml EX-101.LAB 547350
10 vaxx-20220331_pre.xml EX-101.PRE 616909
74 EXTRACTED XBRL INSTANCE DOCUMENT vaxx-20220331_htm.xml XML 709709
Mailing Address 1717 MAIN STREET SUITE 3388 DALLAS TX 75201
Business Address 1717 MAIN STREET SUITE 3388 DALLAS TX 75201 (254) 244-5739
Vaxxinity, Inc. (Filer) CIK: 0001851657 (see all company filings)

IRS No.: 862083865 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41058 | Film No.: 22903167
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences